Home/Filings/4/0000899243-17-008731
4//SEC Filing

CytomX Therapeutics, Inc. 4

Accession 0000899243-17-008731

$CTMXCIK 0001501989operating

Filed

Mar 26, 8:00 PM ET

Accepted

Mar 27, 7:28 PM ET

Size

17.0 KB

Accession

0000899243-17-008731

Insider Transaction Report

Form 4
Period: 2017-03-23
Transactions
  • Sale

    Common Stock

    2017-03-27$18.00/sh650,000$11,700,1955,170,348 total
  • Sale

    Common Stock

    2017-03-23$17.00/sh1,000,000$17,000,2005,820,348 total
Holdings
  • Common Stock

    59,776
  • Common Stock

    59,777
  • Common Stock

    59,776
STARR KEVIN P
10% Owner
Transactions
  • Sale

    Common Stock

    2017-03-27$18.00/sh650,000$11,700,1955,170,348 total
  • Sale

    Common Stock

    2017-03-23$17.00/sh1,000,000$17,000,2005,820,348 total
Holdings
  • Common Stock

    59,776
  • Common Stock

    59,776
  • Common Stock

    59,777
Transactions
  • Sale

    Common Stock

    2017-03-23$17.00/sh1,000,000$17,000,2005,820,348 total
  • Sale

    Common Stock

    2017-03-27$18.00/sh650,000$11,700,1955,170,348 total
Holdings
  • Common Stock

    59,776
  • Common Stock

    59,776
  • Common Stock

    59,777
TRV GP, LLC
10% Owner
Transactions
  • Sale

    Common Stock

    2017-03-23$17.00/sh1,000,000$17,000,2005,820,348 total
  • Sale

    Common Stock

    2017-03-27$18.00/sh650,000$11,700,1955,170,348 total
Holdings
  • Common Stock

    59,776
  • Common Stock

    59,777
  • Common Stock

    59,776
Transactions
  • Sale

    Common Stock

    2017-03-23$17.00/sh1,000,000$17,000,2005,820,348 total
  • Sale

    Common Stock

    2017-03-27$18.00/sh650,000$11,700,1955,170,348 total
Holdings
  • Common Stock

    59,776
  • Common Stock

    59,776
  • Common Stock

    59,777
LEVIN MARK J
10% Owner
Transactions
  • Sale

    Common Stock

    2017-03-23$17.00/sh1,000,000$17,000,2005,820,348 total
  • Sale

    Common Stock

    2017-03-27$18.00/sh650,000$11,700,1955,170,348 total
Holdings
  • Common Stock

    59,776
  • Common Stock

    59,776
  • Common Stock

    59,777
Footnotes (5)
  • [F1]These shares are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
  • [F2]This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.45, inclusive. Each of the reporting persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
  • [F3]These shares are directly held by Starr.
  • [F4]These shares are directly held by Levin.
  • [F5]These shares are directly held by Tepper.

Issuer

CytomX Therapeutics, Inc.

CIK 0001501989

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001501989

Filing Metadata

Form type
4
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 7:28 PM ET
Size
17.0 KB